DB
HUMAW icon

Dmitry Balyasny’s Humacyte Inc Warrant HUMAW Stock Holding History

Dmitry Balyasny’s Portfolio HUMAW Stock Details HUMAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-100,000
Closed -$280K – 2150
2021
Q2 		$280K Hold
100,000
– – ﹤0.01% 1662
2021
Q1 		$299K Buy
+100,000
New +$236K ﹤0.01% 1502

Other funds holding HUMAW

LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
EAM
Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $244M AUM 110.95% 1-Year Est. Return

Dmitry Balyasny's HUMAW Position: Q3 2021 in Review

Dmitry Balyasny sold out of Humacyte Inc Warrant (HUMAW) in Q3 2021, closing a stake of 100,000 shares — an estimated $280K sold.

Dmitry Balyasny first reported a position in HUMAW in Q1 2021 and held it in 2 quarters. The position peaked at $299K in Q1 2021. 13 funds tracked by Wall St. Rank hold HUMAW as of Q3 2021.

  • Dmitry Balyasny reported no remaining Humacyte Inc Warrant position as of Q3 2021 after selling out during the quarter.
  • Dmitry Balyasny sold 100,000 Humacyte Inc Warrant shares in Q3 2021, an estimated $280K.
  • Dmitry Balyasny first reported a position in Humacyte Inc Warrant in Q1 2021 and held it in 2 quarters.
  • Dmitry Balyasny's Humacyte Inc Warrant position peaked at $299K in Q1 2021.
  • 13 funds tracked by Wall St. Rank held Humacyte Inc Warrant as of Q3 2021.

Based on Balyasny Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.